NEW YORK, NY / ACCESSWIRE / June 30, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
ProAssurance Corporation (PRA)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/proassurance-corporation-loss-submission-form?prid=7684&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: April 26, 2019 - May 7, 2020
Allegations against PRA include that: (i) ProAssurance lacked adequate underwriting process and risk management controls necessary to set appropriate loss reserves in its Specialty P&C segment; (ii) ProAssurance failed to properly assess a large national healthcare account that experienced losses far exceeding the assumptions made when the account was underwritten; and (iii) as a result, ProAssurance was subject to materially heightened risk of financial loss and reserve charges.
Sorrento Therapeutics, Inc. (SRNE)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sorrento-therapeutics-inc-loss-submission-form?prid=7684&wire=1
Lead Plaintiff Deadline: July 27, 2020
Class Period: May 15, 2020 - May 22, 2020
Allegations against SRNE include that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Mylan N.V. (MYL)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mylan-n-v-loss-submission-form-2?prid=7684&wire=1
Lead Plaintiff Deadline: August 25, 2020
Class Period: February 16, 2016 - May 7, 2019
Allegations against MYL include that: 1) the Food and Drug Administration's investigation into the Company's manufacturing plant in Morgantown, West Virginia was the result of whistleblower allegations, and not, as Mylan insinuated, the result of a "regular" inspection; and 2) defendants knew, or were reckless in not knowing that, as a result of Mylan's continued efforts to remain uncooperative with the Food and Drug Administration, the Morgantown plant would continue to incur substantial setbacks.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: